Litcius/Paper detail

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Zhiwei Wu, Yaling Hu, Miao Xu, Zhen Chen, Wanqi Yang, Zhiwei Jiang, Minjie Li, Hui Jin, Guoliang Cui, Panpan Chen, Lei Wang, Guoqing Zhao, Yuzhu Ding, Yuliang Zhao, Weidong Yin

2021The Lancet Infectious Diseases575 citationsDOIOpen Access PDF

Topics & Concepts

MedicineTolerabilityPlaceboClinical endpointSeroconversionAdverse effectClinical trialImmunogenicityInternal medicineRandomized controlled trialImmunologyAntibodyAlternative medicinePathologySARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesHeparin-Induced Thrombocytopenia and Thrombosis
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial | Litcius